fashion -WSS

fashion

author：comprehensive 2025-09-27 09:46:56 - browse：89

STAT's Megan Molteni speaks with Feng Zhang in New York on March 21, 2024 — Scientist Feng Zhang, right, is interviewed by reporter Megan Molteni at STAT's Breakthrough Summit East. STAT

When the first biotech companies emerged to capitalize on the revolutionary genome-editing technology CRISPR, Editas Medicine seemed like the pacesetter. It locked up some of the crucial IP, and had behind it the pioneering scientist Feng Zhang of the Broad Institute as one of its founders.

But now, a decade later, Editas is seen as lagging behind its peers. CRISPR Therapeutics, in partnership with Vertex Pharmaceuticals, won the race to get the first CRISPR-based medicine across the finish line. Intellia Therapeutics was the first to show that CRISPR editing could be performed inside the body. Editas, meanwhile, has seen a revolving door among its executives.

So what happened?

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Key House panel plots a new health care package

focus

WSS

Public health communication lessons from Covid

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Biden announces an advanced cancer research initiative

Trader Joe's recalls 10K cases of broccoli cheddar soup over potential foreign material

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

WHO calls for emergency meeting on new China virus, as cases spread

leisure time

fashion

focus

Jerome Adams on the need for new antivirals for Covid

'The boss' wants server deleted: New allegations emerge in Trump indictment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Hospitals, health systems can help patients avoid medical debt

Duchenne breakthrough therapy leaves behind pioneering families

Biden to sign 'historic' executive order on how US military handles sexual assault cases

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Sanofi seeks simpler, safer CRISPR sickle cell cure

Tori Bowie and the unacceptable rates of Black maternal death

VC firm RA Capital starts a new synthetic biology incubator

entertainment

Google and Epic fight stronger regulation of AI in health care

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Custom gene therapy hints at new path for rare disease treatments

Biden jokes that Republicans may impeach him because inflation is starting to cool down

How dance can help nurses traumatized by Covid

As the dark side of IVF slowly comes into focus, even more transparency is needed

explore

focus

knowledge

hotspot